Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul G Corn

Showing results (51-60 of 91) with videos related to

Pageof 10
Sort By:
European Urology Oncology|July 6, 2019
Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II TrialNizar M Tannir, Pavlos Msaouel, Jeremy A Ross, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 5, 2024
Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarizationGuoyu Yu, Paul G Corn, Celia Sze Ling Mak, et al.
Biorxiv : the Preprint Server for Biology|December 11, 2023
Prostate cancer-induced endothelial-to-osteoblast transition generates an immunosuppressive bone tumor microenvironmentGuoyu Yu, Paul G Corn, Celia Sze Ling Mak, et al.
International Journal of Radiation Oncology, Biology, Physics|June 12, 2022
Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTENDAlexander D Sherry, Tharakeswara K Bathala, Suyu Liu, et al.
The Lancet. Oncology|September 14, 2019
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trialPaul G Corn, Elisabeth I Heath, Amado Zurita, et al.
Oncotarget|June 23, 2016
Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancerTheodoros Karantanos, Styliani Karanika, Jianxiang Wang, et al.
International Journal of Radiation Oncology, Biology, Physics|October 30, 2012
PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy eraSean E McGuire, Andrew K Lee, Jasmina Z Cerne, et al.
BJUI Compass|April 27, 2022
Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinomaOmar Alhalabi, Matthew T Campbell, Lianchun Xiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2013
Platinum-based chemotherapy for variant castrate-resistant prostate cancerAna M Aparicio, Andrea L Harzstark, Paul G Corn, et al.
Cell Reports|February 24, 2017
Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 SignalingStyliani Karanika, Theodoros Karantanos, Likun Li, et al.
Pageof 10

Showing results (51-60 of 91) with videos related to

Sort By:
Pageof 10
European Urology Oncology|July 6, 2019
Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II TrialNizar M Tannir, Pavlos Msaouel, Jeremy A Ross, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 5, 2024
Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarizationGuoyu Yu, Paul G Corn, Celia Sze Ling Mak, et al.
Biorxiv : the Preprint Server for Biology|December 11, 2023
Prostate cancer-induced endothelial-to-osteoblast transition generates an immunosuppressive bone tumor microenvironmentGuoyu Yu, Paul G Corn, Celia Sze Ling Mak, et al.
International Journal of Radiation Oncology, Biology, Physics|June 12, 2022
Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTENDAlexander D Sherry, Tharakeswara K Bathala, Suyu Liu, et al.
The Lancet. Oncology|September 14, 2019
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trialPaul G Corn, Elisabeth I Heath, Amado Zurita, et al.
Oncotarget|June 23, 2016
Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancerTheodoros Karantanos, Styliani Karanika, Jianxiang Wang, et al.
International Journal of Radiation Oncology, Biology, Physics|October 30, 2012
PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy eraSean E McGuire, Andrew K Lee, Jasmina Z Cerne, et al.
BJUI Compass|April 27, 2022
Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinomaOmar Alhalabi, Matthew T Campbell, Lianchun Xiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2013
Platinum-based chemotherapy for variant castrate-resistant prostate cancerAna M Aparicio, Andrea L Harzstark, Paul G Corn, et al.
Cell Reports|February 24, 2017
Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 SignalingStyliani Karanika, Theodoros Karantanos, Likun Li, et al.
Pageof 10